US$ 23.28
glp 1 and pregnancy GLP1-RAs: The New Era of Diabetes Weight Loss Management, FAQs in and Lactation Glucagon-like peptide-1 receptor agonist use
Description
This is clearly established in the FDA drug l...

Weight loss drugs have surged in popularity in recent years, transforming the pharmaceutical landscape

While effective, these treatments require monitoring due to potential side effects, especially in non-diabetic patients.This therapeutic advancement represents a revolution in the management of metabolic diseases and obesity.Despite their efficacy in managing obesity and metabolic disorders, GLP-1 and GIP receptor agonists can cause side effects, which are a common reason for therapy discontinuation

New users of GLP-1RAs were matched based on age, demographics, comorbidities and medication use by using 1:1 propensity matching with other glucose-lowering drugs

95% CI 0.97, 1.15)

95% CI 0.94, 1.03)
